“…Due to the various possible limitations with the GI system, hydrophilic macromolecular medicines, proteins primarily polysaccharides, therapeutic peptides, and DNA-based therapies, have low oral bioavailability. A range of tactics has been used to address this issue, including structural drug changes, addition of auxiliary agents, and the production of SEDDS nanocarriers, which are used in various studies as a prominent term for both self-nano- and self-micro emulsifying drug delivery systems (SNEDDS/SMEDDS) and emerge to be a successful method for oral medicines (Page & Szepes, 2021 ). The preparation of SEDDS on an industrial level is economical and simpler than other nanocarriers, including liposomes, micelles, polymer-based nanoparticles, carbon nanotubes, or niosomes, because it is almost like the solution preparation (Mahmood & Bernkop-Schnürch, 2019 ).…”